Open Access Open Access  Restricted Access Subscription Access

Gene Co-Alterations and Survival Benefits in Ovarian Cancer Patients Receiving Platinum-Based Adjuvant Therapy: An Analysis of the Multi-Omics Approach

Pothuraju Ramudu, Aggarapu Susmitha, Gireesh Kumar Eri, Dr. P.V. Kartheek Reddy, Dr. Guduru Rajeswari, Talamanchi Geethika, R. Gayatri

Abstract


Ovarian cancer remains a formidable clinical challenge, with a high rate of recurrence and varied patient response to standard-of-care treatments, particularly platinum-based adjuvant therapy. The traditional reliance on single-biomarker analysis has proven insufficient to capture the complex biological heterogeneity of this disease. This review article explores the transformative role of a multi-omics approach integrating data from genomics, transcriptomics, proteomics, and other high-throughput platforms in unravelling the intricate molecular landscape of ovarian cancer. We summarize recent research that shows how a multi-omics approach can detect clinically important gene co-modifications, which are certain combinations of expression-level and genomic alterations that occur within a single tumor. The study focuses on how patients receiving platinum-based therapy have a higher chance of survival when these observed gene co-alterations are present. We go over the underlying molecular mechanisms that provide increased chemosensitivity, such as deficits in the accelerated DNA damage repair pathway and distinct biomarkers of the tumor microenvironment. We also discuss the bioinformatic developments and computational difficulties needed for successful multi-omics data integration. This review suggests that a multi-omics approach offers a potent new paradigm for prognostic stratification, tailored treatment selection, and the creation of next-generation predictive biomarkers, thus ushering in a new era of precision medicine for patients with ovarian cancer.


Full Text:

PDF

References


Agarwal, R., et al. (2017). Molecular mechanisms of platinum resistance in ovarian cancer. Cancer Treatment Reviews, 53, 78–83.

Ghafouri-Fard, S., et al. (2021). The role of multi-omics in ovarian cancer. Translational Oncology, 14(4), 101035.

Heintz, A. P. M., et al. (2006). A new FIGO staging system for ovarian cancer. International Journal of Gynecological Cancer, 16(3), 856–858.

Heublein, S., et al. (2017). Molecular profiling of ovarian cancer: A literature review. International Journal of Gynecological Cancer, 27(4), 841–850.

Jayson, G. C., et al. (2014). Ovarian cancer. The Lancet, 384(9951), 1376–1388.

Jelovac, D., et al. (2012). Ovarian cancer: From a single entity to a heterogeneous disease. Journal of Oncology, 2012, 1–10.

Ledermann, J. A., et al. (2011). Newly diagnosed and recurrent epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 22(Suppl. 6), vi23–vi27.

Lheureux, S., et al. (2019). Ovarian cancer: A review. The Lancet, 393(10174), 1189–1200.

Perlman, S., et al. (2019). The evolving landscape of ovarian cancer: From classification to treatment. Therapeutic Advances in Medical Oncology, 11, 1–13.

Pinu, F. R., et al. (2019). The integration of multi-omics data in precision medicine. Journal of Clinical Medicine, 8(1), 60.

Sato, K., et al. (2020). Platinum resistance in ovarian cancer. International Journal of Molecular Sciences, 21(24), 9631.

Skates, S. J., et al. (2001). Biomarkers for ovarian cancer detection. The Cancer Journal, 7(1), 58–65.

The Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474(7353), 609–615.

Webb, P. M., et al. (2015). Ovarian cancer: Epidemiology, etiology, and prevention. Obstetrics and Gynecology Clinics of North America, 42(1), 1–18.


Refbacks

  • There are currently no refbacks.